Siegfried Acquires Noramco, Strengthening

Siegfried has acquired Noramco™, a global leader in the production of controlled substances for the pharmaceutical industry, for an undisclosed amount.

Noramco, headquartered in Wilmington, Delaware, specializes in high-purity controlled substances used in medicines for conditions such as attention deficit hyperactivity disorder, pain, and addiction, including abuse-deterrent formulations.

The company operates a global footprint with facilities in Athens, Georgia; Wilmington, Delaware; and Neuhausen, Switzerland, providing analytical data, regulatory assistance, and DEA-compliant security for controlled substances ranging from Schedule I to Schedule III.

This acquisition significantly expands Siegfried's capabilities within the pharmaceutical contract development and manufacturing organization (CDMO) sector.

Noramco's expertise in developing and manufacturing controlled substance active pharmaceutical ingredients (APIs) offers a strategic complement to Siegfried's existing operations.

The integration is expected to leverage Noramco's intellectual property and operational excellence, enhancing the combined entity's ability to provide specialized solutions and secure supply chains for complex pharmaceutical ingredients.

The strategic rationale behind the acquisition centers on strengthening Siegfried's market position and broadening its service portfolio in a highly regulated and specialized segment of the pharmaceutical industry.

By incorporating Noramco's focused capabilities, Siegfried aims to meet the growing demand for high-purity controlled substances and related technical and regulatory support.

This move is designed to create a more comprehensive offering for pharmaceutical clients seeking reliable partners for critical API development and manufacturing.

Looking forward, the combined entity is positioned to deliver an expanded range of specialized pharmaceutical manufacturing services.

The integration of Noramco's unique expertise with Siegfried's broader operational framework is anticipated to enhance innovation and supply security for pharmaceutical companies globally, particularly in the challenging controlled substance market.